Lexeo Therapeutics Statistics
Total Valuation
LXEO has a market cap or net worth of $261.18 million. The enterprise value is $109.45 million.
Important Dates
The next estimated earnings date is Thursday, November 21, 2024, after market close.
Earnings Date | Nov 21, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
LXEO has 33.06 million shares outstanding. The number of shares has increased by 1,114.55% in one year.
Shares Outstanding | 33.06M |
Shares Change (YoY) | +1,114.55% |
Shares Change (QoQ) | +17.95% |
Owned by Insiders (%) | 4.43% |
Owned by Institutions (%) | 49.73% |
Float | 16.98M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 1.66 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.38, with a Debt / Equity ratio of 0.07.
Current Ratio | 9.38 |
Quick Ratio | 9.27 |
Debt / Equity | 0.07 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -471.77 |
Financial Efficiency
Return on equity (ROE) is -74.83% and return on invested capital (ROIC) is -44.64%.
Return on Equity (ROE) | -74.83% |
Return on Assets (ROA) | -39.93% |
Return on Capital (ROIC) | -44.64% |
Revenue Per Employee | n/a |
Profits Per Employee | -$1.33M |
Employee Count | 58 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
Beta (5Y) | n/a |
52-Week Price Change | n/a |
50-Day Moving Average | 9.81 |
200-Day Moving Average | 13.37 |
Relative Strength Index (RSI) | 37.23 |
Average Volume (20 Days) | 337,847 |
Short Selling Information
The latest short interest is 2.06 million, so 6.23% of the outstanding shares have been sold short.
Short Interest | 2.06M |
Short Previous Month | 2.07M |
Short % of Shares Out | 6.23% |
Short % of Float | 12.13% |
Short Ratio (days to cover) | 5.46 |
Income Statement
Revenue | n/a |
Gross Profit | -57.76M |
Operating Income | -82.09M |
Pretax Income | -69.42M |
Net Income | -77.22M |
EBITDA | -81.46M |
EBIT | -82.09M |
Earnings Per Share (EPS) | -$3.90 |
Full Income Statement Balance Sheet
The company has $174.98 million in cash and $10.85 million in debt, giving a net cash position of $164.13 million or $4.96 per share.
Cash & Cash Equivalents | 174.98M |
Total Debt | 10.85M |
Net Cash | 164.13M |
Net Cash Per Share | $4.96 |
Equity (Book Value) | 164.95M |
Book Value Per Share | 4.99 |
Working Capital | 158.27M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$62.95 million and capital expenditures -$474,000, giving a free cash flow of -$63.42 million.
Operating Cash Flow | -62.95M |
Capital Expenditures | -474,000 |
Free Cash Flow | -63.42M |
FCF Per Share | -$1.92 |
Full Cash Flow Statement Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |